Type of Material: COVID-19 Research

KAP assessment as part of the prevention against COVID-19
View Resource

More COVID-19 Resources

Enquête sur les Connaissances, Attitudes et Pratiques (CAP) dans le cadre de la prévention contre la COVID-19 Côte d’Ivoire, Phase 3

Depuis l’émergence du virus SARS-CoV-2 et sa première détection en Côte d’Ivoire en mars 2020, le pays a recensé 87 891 cas et 830 décès (novembre 2022). Le Ministère de la Santé a pris diverses mesures pour réduire la propagation et l’impact du COVID-19, notamment l’autorisation de vaccins contre le COVID-19 que sont AstraZeneca, Pfizer, Sinopharm et Johnson & Johnson (J&J). Avec des objectifs ambitieux de vacciner 70% de la population ivoirienne, comprendre les facteurs de confiance et d’adoption des vaccins est essentiel pour la réponse au COVID-19 et atteindre cet objectif.

Breakthrough ACTION Côte d’Ivoire a menée une enquête auprès des ménages à trois phases portant sur les connaissances, les attitudes et les pratiques afin d’informer la communication des risques et l’engagement communautaire.

  • Toutes les 3 phases réalisées à Abidjan
  • La phase 3, menée à Abidjan et trois sites intérieurs
  • Échantillonnage aléatoire en grappes
  • Les données ont collecté sur des tablettes et extraites quotidiennement pour être nettoyées et analysées

Survey on Knowledge, Attitudes, and Practice (KAP) in the Context of COVID-19 Prevention in Côte d’Ivoire, Phase 3

Since the emergence of the SARS-CoV-2 virus and its first detection in Côte d’Ivoire in March 2020, the country has recorded 87,891 cases and 830 deaths (November 2022). The Ministry of Health has taken various measures to reduce the spread and impact of COVID-19, including the authorization of COVID-19 vaccines from AstraZeneca, Pfizer, Sinopharm, and Johnson & Johnson (J&J). With ambitious goals of vaccinating 70% of the Ivorian population, understanding the drivers of vaccine confidence and uptake is critical to the response to COVID-19 and achieving this goal.

Breakthrough ACTION Côte d’Ivoire conducted a three-phase household survey of knowledge, attitudes and practices to inform risk communication and community engagement.
• All 3 phases conducted in Abidjan
• Phase 3, conducted in Abidjan and three inland sites
• Random cluster sampling
• Data collected on tablets and extracted daily for cleaning and analysis

Source: Johns Hopkins Center for Communication Programs

Date of Publication: February 28, 2023

Regions/Countries

Primary Audience(s)

Channel(s) of Communication

Intervention Level(s)

Language

Topic Areas

Share this Article





Vaccination COVID-19 pour les personnes vivant avec une comorbidité
View Resource

More COVID-19 Resources

Leçons tirées de la recherche sur les perceptions de la vaccination COVID-19 pour les personnes vivant avec une comorbidité en Côte d’Ivoire I Janvier 2023

La Côte d’Ivoire a enregistré 87 966 cas de COVID-19 confirmés, 87 129 guéris et 833 décès et 25 263 932 doses administrées, et 59% de couverture de cible vaccinale (au 09/02/23, MSHPCMU). Éligible au vaccin depuis le début de la vaccination en Côte d’Ivoire, ce sont 9% de porteurs de pathologies chroniques qui ont reçu au moins une dose et 5% complètement vaccinés (Point du 09/02/23, MSHPCMU). Le projet Breakthrough ACTION à travers le financement USAID, appuie le gouvernement de Côte d’Ivoire par le biais des interventions pour le changement social et de comportement (CSC), y compris la recherche et le suivi pour informer sur les activités de vaccination COVID-19. Breakthrough ACTION a recueilli des données qualitatives sur trois sites (Abidjan – Bouaké – San Pedro) afin d’évaluer les perceptions du vaccin contre la COVID-19. Cette analyse se focalise sur les perceptions de la COVID-19 chez les personnes vivant avec une comorbidité (Diabète, HTA, Obésité, VIH..).

Lessons Learned from Research on Perceptions of COVID-19 Vaccination for People Living With Comorbidity in Côte d’Ivoire I January 2023

Côte d’Ivoire has recorded 87,966 confirmed cases of COVID-19, 87,129 cured and 833 deaths, and 25,263,932 doses administered, with 59% coverage of the vaccine target (as of 09/02/23, MSHPCMU). Eligible for the vaccine since the beginning of vaccination in Côte d’Ivoire, 9% of chronic disease carriers have received at least one dose and 5% have been fully vaccinated (as of 09/02/23, MSHPCMU). The Breakthrough ACTION project, through USAID funding, is supporting the government of Côte d’Ivoire through social and behavior change interventions (SBC), including research and monitoring to inform COVID-19 immunization activities. Breakthrough ACTION collected qualitative data in three sites (Abidjan – Bouaké – San Pedro) to assess perceptions of the COVID-19 vaccine. This analysis focuses on perceptions of COVID-19 among people living with co-morbidities (diabetes, hypertension, obesity, HIV, etc.).

Source: Johns Hopkins Center for Communication Programs

Date of Publication: February 28, 2023

Regions/Countries

Primary Audience(s)

Channel(s) of Communication

Intervention Level(s)

Language

Topic Areas

Share this Article





SI C'EST BON POUR MON BÉBÉ, JE VAIS LE FAIRE
View Resource

More COVID-19 Resources

Leçons tirées de la recherche sur les perceptions de la vaccination COVID-19 pour les femmes enceintes en Côte d’Ivoire | Janvier 2023

Bien que la population de Côte d’ivoire ait atteint 58% par rapport à la cible vaccinale, il reste encore du travail à faire pour encourager les personnes ayant des doutes à se faire vacciner. Le gouvernement de la Côte d’Ivoire a autorisé le vaccin Pfizer pour les femmes enceintes depuis janvier 2023 (Circulaire 00103/2023). Breakthrough ACTION soutient le gouvernement de Côte d’Ivoire par le biais des interventions pour le changement social et de comportement (CSC), y compris la recherche et le suivi pour informer sur les activités de vaccination COVID-19. L’équipe de Breakthrough ACTION, en partenariat avec le ministère de la Santé et USAID, a recueilli des données qualitatives sur trois sites afin d’évaluer l’inquiétude suscitée par la COVID-19, les perceptions du déploiement actuel du vaccin, les normes perçues autour de la vaccination, la manière dont la désinformation et d’autres facteurs influencent l’adoption du vaccin. Cette analyse se concentre sur un sous-ensemble de données relatives aux perceptions de la COVID-19 chez les femmes enceintes.

Lessons Learned from Research on Perceptions of COVID-19 Vaccination for Pregnant Women in Côte d’Ivoire | January 2023

Although the population of Côte d’Ivoire has reached 58% of the vaccination target, there is still work to be done to encourage those with doubts to get vaccinated. The government of Côte d’Ivoire has authorized the Pfizer vaccine for pregnant women since January 2023 (Circular 00103/2023). Breakthrough ACTION supports the government of Côte d’Ivoire through social and behavioral change (SBC) interventions, including research and monitoring to inform COVID-19 vaccination activities. The Breakthrough ACTION team, in partnership with the Ministry of Health and USAID, collected qualitative data at three sites to assess concern about COVID-19, perceptions of the current vaccine rollout, perceived norms around vaccination, and how misinformation and other factors influence vaccine uptake. This analysis focuses on a subset of data related to perceptions of COVID-19 among pregnant women.

Source: Johns Hopkins Center for Communication Programs

Date of Publication: February 28, 2023

Regions/Countries

Primary Audience(s)

Channel(s) of Communication

Intervention Level(s)

Language

Topic Areas

Share this Article





View Resource

More Trending Topic Coronavirus COVID-19 Tools Resources

The COVID Tracking Project

The COVID Tracking Project is a volunteer organization launched from The Atlantic and dedicated to collecting and publishing the data required to understand the COVID-19 outbreak in the United States.

Every day, their teams collect data on COVID-19 testing and patient outcomes from all 50 states, 5 territories, and the District of Columbia. The dataset is currently in use by national and local news organizations across the United States and by research projects and agencies worldwide. Their data API (which allows sites and apps to import our dataset automatically) receives about two million requests per day.

On April 15, they launched the COVID Racial Data Tracker, a partnership between the COVID Tracking Project and the Center for Antiracist Research that collects, publishes, and analyzes racial data on the pandemic within the United States.

Source: COVID Tracking Project

Date of Publication: September 22, 2020

SIMILIAR RESOURCES

Tools

Examples

Regions/Countries

Primary Audience(s)

Channel(s) of Communication

Intervention Level(s)

Language

Topic Areas

Share this Article





View Resource

More COVID-19 India Resources

COVID-19 Care in India: The Course to Self-Reliance

The public health response to COVID-19 in India has been highly centralized, resulting in a homogenous strategy applied across a sixth of the world’s population.

India was placed in a nationwide lockdown on March 24, 2020, with restrictions being relaxed in three phases since June. In May 2020, the prime minister called upon the Indian people to be self-reliant. The authors discuss opportunities to modify several aspects of the medical response to echo this sentiment.

They conclude that what is still needed is a plethora of low-tech solutions (especially facial coverings), adherence to science, and societal participation in caring for vulnerable people.

Source: The Lancet

Date of Publication: August 31, 2020

SIMILIAR RESOURCES

Tools

Examples

Regions/Countries

Primary Audience(s)

Channel(s) of Communication

Intervention Level(s)

Language

Topic Areas

Share this Article





View Resource

More COVID-19 Kenya Resources

COVID-19 Kenya – Knowledge Sharing Tracker

This resource tracks reports, presentations, documents, and other tools which are being accumulated as new information about COVID-19 in Kenya is published.

Source: Ministry of Health, Kenya

Date of Publication: August 3, 2020

SIMILIAR RESOURCES

Tools

Examples

Regions/Countries

Primary Audience(s)

Channel(s) of Communication

Intervention Level(s)

Language

Topic Areas

Share this Article